Publication
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
Tjalf Ziemssen, Ann D. Bass, Regina Berkovich, Giancarlo Comi, Sara Eichau, Jeremy Hobart, Samuel F Hunter, Christopher LaGanke, Volker Limmroth, Daniel Pelletier, Carlo Pozzilli, Sven Schippling, Livia Sousa, Anthony Traboulsee, Bernard M. J. Uitdehaag, Bart Van Wijmeersch, Zia Choudhry, Nadia Daizadeh, Barry A. Singer
CNS Drugs, July 2020, Springer Science + Business Media
DOI: 10.1007/s40263-020-00749-x